Tiger Brokers

BUZZ-Vor Bio jumps after late-stage data for immune disorder drug

Reuters
Aug 13
BUZZ-Vor Bio jumps after late-stage data for immune disorder drug

** Shares of drug developer Vor Bio VOR.O rise ~37% to $2.26 premarket

** Co and Chinese partner RemeGen's 688331.SS experimental drug met the main goal of a late-stage study in China for the treatment of Sjögren's disease

** VOR says the drug, telitacicept, significantly reduced disease severity in patients with the autoimmune condition that damages the glands that produce and control moisture in the body

** Telitacicept showed a favorable safety profile in the study - VOR

** VOR signed a licensing deal in June to develop and commercialize telitacicept outside China

** Telitacicept is being tested to treat another immune disorder, generalized myasthenia gravis, in a global late-stage study

** Up to last close, stock was up 49.5% YTD

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10